InvestorsHub Logo
Followers 0
Posts 441
Boards Moderated 0
Alias Born 07/16/2014

Re: None

Wednesday, 05/29/2024 9:15:20 AM

Wednesday, May 29, 2024 9:15:20 AM

Post# of 188
Analysts Think $CRDL is Undervalued

Last week, Canaccord Genuity lifted the PT to $8 from $6 on Cardiol Therapeutics Inc (NASDAQ: CRDL) – Potential gain of 260% from CMP.

Analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and with a PT of $9.

Moreover, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.

$RSLS $MRNA $NVAX $INSM $KTRA $VTYX $SCPX
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRDL News